Prediction of Costs, Effectiveness, and Disease Control of a Population-Based Program Using Home Sampling for Diagnosis of Urogenital Chlamydia trachomatis Infections


    loading  Checking for direct PDF access through Ovid

Abstract

Objective:To estimate the incremental effects and costs of a home sampling screening approach for Chlamydia trachomatis over the current in-office screening practice in Denmark.Goals:To assess the effect of a new screening strategy.Study Design:A dynamic Monte Carlo model estimated prevalence and incidence over 10 years for a home sampling screening program and the current in-office screening. Subsequently, the incremental number of major outcomes averted (MOA) and the related direct and indirect costs were estimated.Results:Infection prevalence after 10 years was 1.0% with a home sampling program and 4.2% with the current in-office screening practice. The total costs per MOA reached $3186 during the first year of the home sampling strategy, but in year 4, the accumulated indirect costs offset the direct costs, and the program henceforth saved society costs.Conclusions:Home sampling should be considered a relevant alternative to the current practice of in-office screening.

    loading  Loading Related Articles